Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board
23 Agosto 2021 - 9:00AM
Heat Biologics, Inc. (“Heat”)
(NASDAQ: HTBX), a clinical-stage
biopharmaceutical company focused on developing first-in-class
therapies to modulate the immune system, announces the addition of
Mark Pryor, former US Senator from the State of Arkansas, to the
Company’s Biothreat Advisory Board.
Former US Senator Mark Pryor currently serves
with the premier law firm, Brownstein Hyatt Farber Schreck. He is a
former two-term U.S. senator and Arkansas attorney general. During
his 12 years representing Arkansas in the Senate, he worked across
the aisle to pass more than 70 pieces of legislation on a range of
critical issues, including homeland security and defense. Sen.
Pryor served on several high-profile committees during his tenure,
including Appropriations; Armed Services; Commerce, Science and
Transportation; Homeland Security and Governmental Affairs.
Jeff Wolf, Chief Executive Officer of Heat,
commented, “As a leader on the Armed Services as well as the
Homeland Security and Governmental Affairs committees, Senator
Pryor brings unique expertise in policy and government affairs to
our biothreat efforts. We look forward to leveraging Senator
Pryor’s knowledge as we advance our new biothreat initiatives.”
Senator Pryor joins David Lasseter, Former
Deputy Assistant Secretary of Defense for Countering Weapons of
Mass Destruction; Former US Representative Jack Kingston, who also
serves as the Secretariat of the Alliance for
Biosecurity; Andrew C. Weber, Former Assistant Secretary of
Defense for Nuclear, Chemical & Biological Defense Programs;
and Dr. Gregory Koblentz, Associate Professor at George Mason
University and leading expert on chemical and biological
weapons.
About Heat Biologics, Inc.Heat
Biologics is a biopharmaceutical company focused on developing
first-in-class therapies to modulate the immune system. Heat’s gp96
platform is designed to activate immune responses against cancer or
infectious diseases. The Company has multiple product candidates in
development leveraging the gp96 platform, including HS-110, which
has completed enrollment in a Phase 2 trial, various infectious
disease/biological threat programs in preclinical development and a
pipeline of proprietary immunomodulatory antibodies and cell-based
therapies, including PTX-35 and HS-130 in Phase 1 clinical
trials.
For more information, please
visit: www.heatbio.com, and also follow us
on Twitter.
Forward Looking StatementThis
press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 on
our current expectations and projections about future events. In
some cases, forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectation, and assumptions and include
statements regarding the contributions to be made by Mark Pryor the
advisory board and leveraging Senator Pryor’s knowledge as Heat
advances its new biothreat initiatives. These statements are
subject to a number of risks and uncertainties, many of which are
difficult to predict, including the ability of Heat to successfully
develop a new biosecurity/biodefense initiative and benefit from
the contributions of the advisory board, the ability of Heat's
therapies to perform as designed, to demonstrate safety and
efficacy, as well as results that are consistent with prior
results, the ability to enroll patients and complete the clinical
trials on time and achieve desired results and benefits, especially
in light of COVID-19, Heat's ability to obtain regulatory approvals
for commercialization of product candidates or to comply with
ongoing regulatory requirements, regulatory limitations relating to
Heat's ability to promote or commercialize its product candidates
for specific indications, acceptance of its product candidates in
the marketplace and the successful development, marketing or sale
of products, Heat's ability to maintain its license agreements, the
continued maintenance and growth of its patent estate, its ability
to establish and maintain collaborations, its ability to obtain or
maintain the capital or grants necessary to fund its research and
development activities and its cash and short-term investments
providing significant runway to fund Heat’s current clinical
programs and further expand Heat’s therapeutic portfolio , its
ability to continue to maintain its listing on the Nasdaq Capital
Market and its ability to retain its key scientists or management
personnel, and the other factors described in Heat's annual report
on Form 10-K for the year ended December 31, 2020 filed with the
SEC, and other subsequent filings with the SEC. The information in
this release is provided only as of the date of this release, and
Heat undertakes no obligation to update any forward-looking
statements contained in this release based on new information,
future events, or otherwise, except as required by law.
Media and Investor Relations ContactDavid
Waldman+1 919 289 4017investorrelations@heatbio.com
Heat Biologics (NASDAQ:HTBX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Heat Biologics (NASDAQ:HTBX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024